Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Nesuparib · 1 trial · 5 indications
In Part A, To evaluate dose-limiting toxicities(DLTs) of combination maintenance treatment with pembrolizumab and nesuparib during the 21 days from first nesuparib and pembrolizumab administration, and to establish a recommended Phase 2 dose(RP2D) and dosing schedule.
The time from randomization to the time when Progressive disease(PD) is first confirmed after administration of the first investigational drug (Pembrolizumab) or until death without disease progression.
| Arm | Type | Description |
|---|---|---|
| Part B - Pembrolizumab monotherapy | EXPERIMENTAL | Chemotherapy Treatment Pembrolizumab 200 mg IV Day 1 + Paclitaxel 175mg/m2 IV over 3 hours Day 1 + Carboplatin AUC 5 IV Day 1 x 6 cycles (one cycle = 3 weeks Maintenance Treatment Pembrolizumab 400 mg IV Day 1 x up to 14 cycles (o ne cycle = 6 weeks ) Maximum number of Pembrolizumab cycles (Chemotherapy Treatment + maintenance Treatment ) = 20 |
| Part B - Pembrolizumab and nesuparib combination therapy | EXPERIMENTAL | Combination therapy Chemotherapy Treatment Pembrolizumab 200 mg IV Day 1 + Paclitaxel 175mg/m2 IV over 3 hours Day + Carboplatin AUC 5 IV Day 1 x 6 cycles (one cycle = 3 weeks) Maintenance Treatment Pembrolizumab 400 mg IV Day 1 + Nesuparib 150mg or 100mg QD PO x up to 14 cycles (o ne cycle = 6 weeks ) Maximum number of Pembrolizumab cycles (Chemotherapy Treatment + maintenance Treatment ) = 20 |
| Part A - Safety Run-in Phase | EXPERIMENTAL | Chemotherapy Treatment: Pembrolizumab 200 mg IV Day 1 + Paclitaxel 175mg/m2 IV over 3 hours Day 1 + Carboplatin AUC 5 IV Day 1 x 6 cycles (one cycle = 3 weeks) Maintenance Treatment: Pembrolizumab 400 mg IV Day 1 + Nesuparib 150mg or 100mg QD PO x up to 14 cycles (one cycle = 6 weeks) Maximum number of Pembrolizumab cycles (Chemotherapy Treatment + Maintenance Treatment) = 20 |
| Name | Type | Description |
|---|---|---|
| Nesuparib | DRUG | Nesuparib 150mg or 100mg, QD, PO |
| Pembrolizumab | DRUG | Pembrolizumab 400mg, IV, Q6W |
\[Inclusion Criteria\] 1. Patient must be female ≥ 19 years of age 2. Histologic confirmation of the original primary tumor is required. Patients with the following histologic types are eligible: Endometrioid adenocarcinoma, serous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcino...
Top 20 of 50 competitors